Trevi Therapeutics, Inc. (TRVI) stock
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.65+0.03 (+0.22%)
Close on Nov 13, 2026Market cap $1.94BP/E –Yield –
Trevi Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Trevi Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$69.99M. For fiscal 2025 it was -$49.18M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$49.18M | – |
| FY2024 | Dec 31, 2024 | -$51.38M | – |
| FY2023 | Dec 31, 2023 | -$33.80M | – |
| FY2022 | Dec 31, 2022 | -$29.86M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$24.45M | – |
| Q2 FY2026 | Jun 30, 2026 | -$20.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.88M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.88M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.43M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.21M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.05M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.25M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.90M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.01M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.35M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.54M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.64M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.01M | – |
See a number that looks wrong?